Results for bsep translation from English to Latvian

furthermore, ambrisentan does not induce mrp2, pgp or bsep.
turklāt ambrisentāns neinducē mrp2, pgp vai bsep.

in vitro, crizotinib is not an inhibitor of bsep at clinically relevant concentrations.
in vitro krizotinibs klīniski nozīmīgā koncentrācijā nav bsep inhibitors.

based on in vitro data, a potential for gzr to inhibit bsep cannot be excluded.
pamatojoties uz in vitro datiem, nevar izslēgt grazoprevīra spēju inhibēt bsep.

in vitro studies in rat hepatocytes also showed that ambrisentan did not induce pgp, bsep or mrp2 protein expression.
in vitro pētījumos ar žurku hepatocītiem arī konstatēts, ka ambrisentāns neinducēja pgp, bsep vai mrp2 proteīnu ekspresiju.

lenvatinib is not a substrate for oat1, oat3, oatp1b1, oatp1b3, oct1, oct2, or the bsep.
lenvatinibs nav oat1, oat3, oatp1b1, oatp1b3, oct1, oct2 vai bsep substrāts.

at clinically relevant concentrations avanafil is not an inhibitor of oatp1b1, oatp1b3, oct1, oct2, oat1, oat3 and bsep.
klīniski pietiekamā koncentrācijā avanafils nav oatp1b1, oatp1b3, oct1, oct2, oat1, oat3 un bsep inhibitors.

liver dysfunction risk may also be increased when medicinal products that are inhibitors of the bile salt export pump (bsep), e. g., rifampicin, glibenclamide and cyclosporine a (see sections 4.3 and 4.5), are co- administered with bosentan, but limited data are available.
aknu darbības traucējumu risks var palielināties arī tad, ja vienlaicīgi tiek lietoti žultsskābju sāļu izvadīšanas sūkņa inhibitori, piem., rifampicīns, glibenklamīds un ciklosporīns a (sk. apakšpunktus 4. 3. un 4. 5.), taču dati par to ir ierobežoti.